
Artrya, listed on the Australian Securities Exchange (ASX) as AYA, is developing AI coronary imaging technology.
The technology aims to improve diagnosis of heart disease globally.
How different news outlets are covering this story.
AI comparison of narrative angles and framing
Center
Slightly neutral overall tone across the coverage.
Critical angles and context underreported by specific political desks
Left-leaning publications provided minimal initial coverage on "Artrya (ASX:AYA): AI Coronary Imaging Technology Targets Global Heart Disease Diagnosis Market", dedicating fewer reporting resources to early investigative filings.
Right-leaning outlets offered scarce direct reporting on "Artrya (ASX:AYA): AI Coronary Imaging Technology Targets Global Heart Disease Diagnosis Market", focusing editorial priority on broader ideological commentary.
Get every side of the week's biggest story in your inbox.
Projected milestones, strategic ramifications, and attributed stakeholder perspectives
Heart disease is a significant global health issue
“Industry experts emphasize that institutional stability and consumer trust will hinge on the effectiveness of upcoming implementation steps.”
— Kalkine Media Editorial Desk
Multi-factor evaluation of reporting rigor, editorial baselines, and ownership transparency
Evaluated across 1 reporting source (0% Left · 100% Center · 0% Right)
Lead reporting from Kalkine Media. Bias rating reflects overall narrative framing and source selection.
Historical editorial baseline for Kalkine Media
Historical editorial rating for Kalkine Media based on high factuality standards and corporate governance.
Multi-factor accuracy index for Kalkine Media and related desks based on verifiable sourcing and editorial standards.
Factuality: High 100%
Ownership: Kalkine Media (Corporate)
Key moments and updates
Understanding the bigger picture
Loading comments…
Developing headlines and related coverage across the wire